Chronic agmatine treatment prevents olanzapine-induced obesity and metabolic dysregulation in female rats

Madhura P Dixit, Shivkumar S Sammeta, Mrunali D Dhokne, Shubhada Mangrulkar, Manoj A Upadhya, Milind J Umekar, Brijesh G Taksande, Nandkishor R Kotagale

Research output: Contribution to journalArticlepeer-review

Abstract

Antipsychotic-induced obesity affects millions of people and is a serious health condition worldwide. Olanzapine is the most widely prescribed antipsychotic agent with high obesogenic potential. However, the exact mechanism by which it causes its metabolic dysregulation remains poorly understood. In this study, we investigated the effect of agmatine in olanzapine-induced metabolic derangements in Female Sprague-Dawley rats. Repeated olanzapine administration for 28 days increased body weight while treatment with agmatine from days 15 to 28 prevented the body weight gain induced by olanzapine without any alteration in food intake. Repeated agmatine treatment decreased the elevated feeding efficiency and adiposity index, as well as improved dysregulated lipid metabolism induced by olanzapine. Increased activity of fatty acid synthase (FAS) and decreased expression of carnitine palmitoyl transferase-1 (CPT-1) were detected in chronic olanzapine-treated rats. Although agmatine treatment did not alter FAS activity, it increased CPT-1 activity. It is possible that the inhibitory effect of agmatine on weight gain and adiposity might be associated with increased mitochondrial fatty acid oxidation and energy expenditure in olanzapine-treated rats. We suggest that agmatine can be explored for the prevention of obesity complications associated with chronic antipsychotic treatment.
Original languageEnglish
Pages (from-to)69-77
Number of pages9
JournalBrain research bulletin
Volume191
Early online date19 Oct 2022
DOIs
Publication statusPublished - 1 Dec 2022

Keywords

  • Olanzapine
  • Agmatine
  • Antipsychotics-induced obesity
  • Metabolic syndrome

Fingerprint

Dive into the research topics of 'Chronic agmatine treatment prevents olanzapine-induced obesity and metabolic dysregulation in female rats'. Together they form a unique fingerprint.

Cite this